We describe an opioid-tolerant patient with severe acute pain which was unrelieved by morphine and ketamine via intravenous patient-controlled analgesia, but almost totally relieved by methadone. In the previous 24 hours, 509 mg of intravenous morphine and 769 mg of ketamine had been used and this was replaced by 200 mg of oral methadone. This implies that the success of methadone in morphine tolerant patients chiefly involves factors other than its role as an N-methyl-D-aspartate receptor antagonist, and that methadone should be considered as a replacement for morphine when the N-methyl-D-aspartate antagonist ketamine has proved ineffective.
For acute pain management, a combination of analgesics is generally more effective than opioid analgesia alone 1 . There has been a revival of interest in ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, as an adjunct to opioid analgesia postoperatively 2 . As the NMDA receptor has been shown to be important in the development of central sensitization and opioid tolerance 3, 4 , ketamine has also been recommended for opioid-tolerant patients and for neuropathic pain 4, 5 .
In cancer pain that is poorly responsive to morphine, substituting a different opioid, such as methadone, is a more popular and well-established strategy than adding ketamine 5, 6, 7 . Methadone has a long and variable half-life, which makes it more difficult to use than morphine and less appropriate as a first line agent 5 . However, methadone has some distinctive properties, including its action as an NMDA antagonist 4 , that may explain its success in treating cancer pain. It is thus a potentially useful alternative in some cases of acute pain.
CASE HISTORY
A 25-year-old, 60 kg man with a history of intravenous (IV) opioid abuse was admitted to hospital after major trauma. He had suffered a fall from a height of about seven metres in unusual circumstances, resulting in fractures to his face, left femur and upper limbs.
He had been on the methadone treatment program receiving 65 mg/day until seven weeks prior to admission, ostensibly removing himself in an attempt to "get his life in order", and because he believed methadone gave him bad dreams. However, after suffering withdrawal symptoms, he had received slowrelease morphine (MS Contin, Pharmacia and Upjohn Pty Ltd) 100 mg bd from his general practitioner. He admitted taking one or two tablets of diazepam per day and smoking cannabis, but denied ongoing IV drug usage and had no visible recent injection sites.
After resuscitation the patient underwent surgery for internal fixation of his femoral fracture under general anaesthesia. For initial pain relief he received 115 mg IV morphine over the first eight hours in hospital, a femoral nerve block at the time of surgery, and regular paracetamol 4 g per day. Despite his upper limb fractures he was able to use his hands, and so was commenced on IV PCA morphine with 2 mg boluses, 5-minute lockout and 2 mg/h as a background infusion.
The morning after surgery (day 2) he reported that his pain was "severe" (on a verbal rating score) both at rest and with movement, so regular naproxen 500 mg bd was added and MS Contin 100 mg bd was recommenced. Despite these additional measures and receiving 310 mg of morphine by PCA over the next 24 hours, the patient continued to complain of severe pain at rest and with movement, and was unwilling to move in bed. At times his level of sedation had been "moderate" (2 on a 0-to-3 scale), but was "mild" when seen on the morning of day 3.
Ketamine was added to the PCA mixture at the same dose as morphine, with consequent improvement in mobility and reported pain (mild at rest, moderate with movement). Over days 4 to 6 there was also some reduction in morphine requirement (average 241 mg/day) and in sedation. However, after further surgery to facial fractures on day 6 and to an elbow fracture on day 9, his pain worsened and his morphine requirement steadily increased.
After his elbow surgery the patient complained of "unbearable" pain that was unrelieved overnight despite additional morphine boluses and an increase in the PCA ketamine concentration. When seen the next morning (day 10), the patient was still distressed with severe pain at rest, but not sedated or confused. His arm was tender but he tolerated physical examination to exclude a surgical complication, and there were no myoclonic jerks evident. In the previous 24 hours he had received 509 mg of IV morphine and 769 mg of ketamine, as well as oral paracetamol, naproxen and 100 mg of oral morphine. His hepatic and renal function were normal, and there were no electrolyte abnormalities.
It was decided to stop morphine and ketamine, but continue with paracetamol and naproxen. The patient was told that morphine might be worsening his pain, and replacement with oral methadone 200 mg was proposed. He reluctantly agreed, despite his dislike for methadone, and his concern that the pain would worsen further. However, when seen two hours after the dose of methadone (three hours after ceasing PCA) the patient was much calmer, only mildly sedated, and had minimal pain even with movement.
He remained comfortable overnight and slept well without further opioid analgesia. The next day he was virtually pain-free and quite cheerful, in striking contrast to the previous ten days. He attributed his improvement to the methadone, and expressed his surprise that it had worked so quickly. Methadone was continued at 50 mg qid for two days before reduction to 30 mg qid. The patient remained comfortable and was discharged from hospital on day 20, taking methadone 70 mg/day. However, two weeks after discharge he recommenced slow release morphine for control of his opioid addiction, because he still preferred it to methadone for long-term use.
DISCUSSION
This patient had severe acute pain, unrelieved by substantial doses of morphine and ketamine, that resolved rapidly after commencing oral methadone. There are several possible explanations for this improvement.
The patient may have improved simply by ceasing the morphine. A syndrome of morphine-related hyperalgesia, allodynia, myoclonus and agitation has been described in cancer patients. This has been attributed to accumulation of morphine 3-glucuronide [5] [6] [7] [8] [9] [10] . Our patient did have hyperalgesia, but not clearly more than would be expected after trauma and surgery 11 , especially with inadequate pain relief. He did not have myoclonus, which may be more specific of opioid toxicity 12 . In addition, with presumed morphine 3-glucuronide toxicity resolution of symptoms usually takes several hours or days after stopping morphine 9,10 , whereas our patient improved after only 2 to 3 hours.
Methadone and morphine may interact differently with mu opioid receptors. In recent years, at least seven different mu opioid receptor subtypes have been isolated 13 . Because of their dissimilar structures, morphine and methadone are believed to act on different spectra of these subtypes, so that a change to methadone may allow it to act on receptors to which tolerance has not developed 7, 13 .
Much recent speculation about the success of methadone in cancer pain has focused on its role as an NMDA receptor antagonist [5] [6] [7] . However, the importance of this mechanism is questionable in our patient, because we were already using the NMDA receptor antagonist ketamine. Nevertheless the NMDA receptor exists as multiple subtypes and at different sites 14, 15 , so it remains possible that a different antagonist could play a role in analgesia even when another has failed.
Methadone also differs from morphine in that it has significant activity at delta opioid receptors 6, 7 . The importance of this is unclear, although studies on the role of delta receptor agonists have shown their ability to potentiate mu opioid activity 16 , as well as exerting an analgesic effect in their own right 17 . Methadone also inhibits the uptake of 5-hydroxytryptamine and norepinephrine. This may contribute to its analgesic properties 18 , although it appears less effective than tramadol in this respect 19 .
Ketamine can cause dysphoria 2 , so cessation might have contributed to the patient's emotional improvement, despite it having been well tolerated and beneficial initially. However, as the patient had received ketamine for seven days and ketamine has an elimination half-life of about three hours 20 , its cessation is unlikely to have been a major factor in the patient's rapid improvement.
Finally, spontaneous resolution of pain, or a psychological explanation, would appear unlikely reasons for the patient's improvement in view of the extent of his injuries, the duration and severity of pain, and his initial reluctance to try methadone. When replacing morphine with methadone, the starting dose must be carefully individualized 21 . For each patient one should consider factors such as the duration of morphine therapy and dose required, the presence of side-effects (especially sedation), the type and severity of pain, the use of other drugs, and the presence of organ dysfunction.
The equianalgesic dose ratio for parenteral morphine and methadone, as determined by single dose studies, is 1:1 21 . However, because of the reasons already discussed, this is very misleading for patients on chronic therapy. For morphine tolerant patients, a starting oral methadone to oral morphine ratio of 1:4 to 1:10 is commonly recommended 5, 7, 9, 21, 22 .
For reasons of safety, an initial maximum oral methadone dose of 30 mg has been suggested when oral morphine dose is greater than 300 mg 6 . Further methadone can be titrated as required, although with this approach, adequate pain relief may take two or three days to achieve 6, 22 . For our patient, we believe this conservative strategy would have been unacceptable because of the severity of his pain, and unduly cautious in view of his lack of sedation, his marked tolerance to morphine and his previous experience with methadone. He was also being closely observed by nursing staff, with Acute Pain Service personnel immediately available.
We are unaware of any precedent for determining a methadone dose for a patient on morphine and ketamine. However, in several studies ketamine has shown a morphine sparing effect of 40 to 60% 2 , so we made the assumption that IV morphine 500 mg with ketamine (the final 24 hour dose) was equivalent to IV morphine 1000 mg alone. As methadone 200 mg orally is equivalent to 100 mg IV 21 , this dose represents an IV methadone:morphine conversion ratio of about 1:10. This was effective in relieving pain without side-effects.
In summary, we described an opioid tolerant patient with severe acute pain, who had an excellent analgesic response to methadone, after the failure of morphine and ketamine. This suggests that the commonly cited mechanism of NMDA antagonism is not central to the success of opioid substitution with methadone. Although several factors may have contributed, perhaps the action of methadone on mu receptor subtypes, at which tolerance had not developed, was the most important in this case. Whatever the precise mechanisms, methadone should be considered for patients with acute pain unrelieved by morphine, even when ketamine has also been tried.
